PMID- 11672566
OWN - NLM
STAT- MEDLINE
DCOM- 20011204
LR  - 20190624
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 424
IP  - 3
DP  - 2001 Jul 27
TI  - Basal tonic release of nitric oxide coupled to cGMP production regulates the 
      vascular reactivity of the mesenteric bed.
PG  - 221-7
AB  - To reveal a basal production of nitric oxide (NO) and guanosine 3',5' cyclic 
      monophosphate (cGMP) in the rat arterial mesenteric bed, mesenteries were 
      perfused in the absence and in the presence of selective blockers of the 
      L-arginine cascade. Endothelium removal or inhibition of NO synthase 
      significantly reduced the release of NO and tissue cGMP. A significant 
      correlation between these messengers was shown. Blockade of soluble guanylyl 
      cyclase with 0.3-10 microM 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) only 
      reduced basal cGMP production; 1-100 nM sildenafil (Sild), an inhibitor of 
      phosphodiesterase V, increased basal tissue cGMP without modifying the release of 
      NO. Acetylcholine (0.01-10 microM) caused a concentration-dependent rise in NO 
      and cGMP evoking a proportional vasodilatation, demonstrating the interdependence 
      between these messengers and vascular reactivity. Endothelium removal or NO 
      synthase blockade reduced the acetylcholine-induced increase of messengers and 
      the vasodilatation. ODQ attenuated only the increase in cGMP and the 
      vasodilatation, while sildenafil increased cGMP without significantly altering 
      luminal NO release. The present results highlight a tonic release of NO and its 
      involvement in endothelial-smooth muscle signaling; NO and cGMP are determinants 
      of vascular reactivity.
FAU - Buvinic, S
AU  - Buvinic S
AD  - Centro de Regulacion Celular y Patologia, Instituto Milenio de Biologia 
      Fundamental y Aplicada, MIFAB, P. Universidad Catolica de Chile, Casilla 114-D, 
      Santiago, Chile.
FAU - Huidobro-Toro, J P
AU  - Huidobro-Toro JP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Oxadiazoles)
RN  - 0 (Piperazines)
RN  - 0 (Purines)
RN  - 0 (Quinoxalines)
RN  - 0 (Sulfones)
RN  - 0 (Vasoconstrictor Agents)
RN  - 0 (Vasodilator Agents)
RN  - 2149-70-4 (Nitroarginine)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 94ZLA3W45F (Arginine)
RN  - BW9B0ZE037 (Sildenafil Citrate)
RN  - H2D2X058MU (Cyclic GMP)
RN  - N9YNS0M02X (Acetylcholine)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - Acetylcholine/pharmacology
MH  - Animals
MH  - Arginine/pharmacology
MH  - Cyclic GMP/*biosynthesis
MH  - Dose-Response Relationship, Drug
MH  - Endothelium, Vascular/physiology
MH  - Enzyme Inhibitors/pharmacology
MH  - Male
MH  - Mesenteric Arteries/drug effects/metabolism/*physiology
MH  - Nitric Oxide/*metabolism
MH  - Nitroarginine/pharmacology
MH  - Norepinephrine/pharmacology
MH  - Oxadiazoles/pharmacology
MH  - Piperazines/pharmacology
MH  - Purines
MH  - Quinoxalines/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Sildenafil Citrate
MH  - Sulfones
MH  - Vasoconstriction/drug effects
MH  - Vasoconstrictor Agents/pharmacology
MH  - Vasodilation/drug effects/*physiology
MH  - Vasodilator Agents/pharmacology
EDAT- 2001/10/24 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/10/24 10:00
PHST- 2001/10/24 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/10/24 10:00 [entrez]
AID - S0014299901011657 [pii]
AID - 10.1016/s0014-2999(01)01165-7 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2001 Jul 27;424(3):221-7. doi: 10.1016/s0014-2999(01)01165-7.